| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 |
| 25 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
This SUB-SUBLEASE AGREEMENT (this “Sub-Sublease”) is made as of August 21, 2026 (the “Effective Date”), by and between WAYFAIR LLC, a Delaware limited liability company having an office at 4 Copley Place, Boston, Massachusetts 02116 (“Su... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth |
| 28 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BOSTON, July 28, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Je... |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Bicara Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in ... |
| 21 May 2026 |
8-K: Other Events
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
-- Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 -- |
| 26 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Bicara Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (i) 7,175,000 shares of its common stock, par value $0.0001 per shar... |
| 19 Feb 2026 |
8-K: Other Events
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen |
| 12 Jan 2026 |
8-K: Other Events
Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
ESMO Asia 2025 Clinical Update December 6, 2025 FICERA: enabling tumor penetration to drive deep and durable responses in HPV-neg HNSCC |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2025, Bicara Therapeutics Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in ... |
| 06 Jun 2025 |
8-K: Entry into a Material Definitive Agreement
On June 2, 2025, Bicara Therapeutics Inc. (the “Company”) entered into a Sublease Agreement (the "Sublease) with J.W. Childs Associates, L.P, (the “Sublandlord”), effective upon receipt of the consent of Columbia Reit – 116 Huntington, L... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting |
| 27 Mar 2025 |
8-K: Results of Operations and Financial Condition
Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Fighting cancer with precision and power. Corporate Presentation | January 2025 © 2024 - 2025 Bicara Therapeutics |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC |
Loading...